SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Xcellerant Ventures welcomes Lenoss Medical into our Venture Fund I portfolio. Lenoss Medical is disrupting the treatment of spinal fractures with their OsteoPearl VBA System. This minimally invasive and cement-free technology delivers a fully biologic solution to stabilize spinal fractures and utilizes the natural healing properties of healthy bone. “There is no longer a need to utilize cement to treat osteoporotic spinal fractures. This is a common-sense solution that eliminates a major risk associated with vertebral compression fracture surgeries and promotes healing at the same time. Their CEO Dom Messerli is a visionary leader, and we are thrilled to be a major investor in this round of financing,” says Xcellerant Ventures General Partner John Shufeldt.
Xcellerant Ventures identifies and invests in innovative companies that deliver transformative solutions in the healthcare sector. Lenoss Medical is a Rhode Island-based company that recently won the second annual ASU InvestU HealthTech Startup Pitch Event and is now opening an office in Phoenix, AZ to service the western United States. Lenoss Medical CEO Dom Messerli states, “With the support of our investors, now including Xcellerant Ventures, we are thrilled to be able to accelerate our OsteoPearl commercial and development strategies providing physicians a biological option for treating osteoporotic Vertebral Compression fractures. We are excited to bring Xcellerant’s leadership and depth of experience to our board of directors; joining the team as a founder friendly collaborator with unique insights and experience in the health care sector.”
For more information, contact Xcellerant Ventures' Tiffany Youtchoko at tyoutchoko@xcellerantventures.com or Lenoss Medical’s John Williams at john.williams@lenoss.com or visit www.xcellerantventures.com and www.lenoss.com.
